New Menopause Hot Flash Medication: Lynkuet vs Veozah (2026 Guide)
The short version
The new menopause hot flash medication everyone is asking about is Lynkuet (elinzanetant), FDA-approved October 24, 2025 — a once-daily, non-hormonal pill for moderate-to-severe hot flashes and night sweats. The other newer non-hormonal pill, Veozah (fezolinetant), has been on the market since 2023 but carries a liver boxed warning. Neither is a hormone.
The part almost nobody is telling you
“Non-hormonal” does not automatically mean “safer.” Two of the three FDA-approved non-hormonal hot flash pills carry boxed warnings. Meanwhile, in February 2026, the FDA removedboxed warnings from six hormone products. So the real question isn’t “hormone or not” — it’s “which option fits your body, your health history, your budget, and your tolerance for blood draws?”
Disclosure:The HRT Index is an independent comparison resource for HRT telehealth providers. We may earn a commission if you choose a provider through one of our links. Our medical facts, safety details, and recommendations come from the cited sources and honest fit — not from who pays us. We don’t rank medications by payout.
| If your real question is… | Start here on this page |
|---|---|
| “What’s the newest pill?” | Lynkuet — jump to the comparison below |
| “What’s that other new one?” | Veozah — and why it needs blood tests |
| “Is this a hormone?” | No — here’s what non-hormonal really means |
| “Is the newest one actually safer?” | The boxed-warning twist most people miss |
| “What will it cost me?” | The real 2026 prices and savings options |
| “What if I can take hormones?” | When hormone therapy may be the better call |
Find my hot flash treatment path →
Free 60-second quiz. No diagnosis, no prescription — just a clear, personalized plan and the exact questions to bring to a licensed clinician.
Take the free 60-second quiz →What is the new menopause hot flash medication?
The newest U.S. medication for menopause hot flashes is Lynkuet (elinzanetant), a prescription, non-hormonal pill approved by the FDA in October 2025for moderate-to-severe vasomotor symptoms (“vasomotor symptoms,” or VMS, is the medical term for hot flashes and night sweats). It is not estrogen, progesterone, or hormone therapy. It works on brain signals that control body temperature.
Lynkuet is the third non-hormonal medication the FDA has approved specificallyfor menopausal hot flashes — after Brisdelle and Veozah — and the first that blocks two brain receptors at once. You take Lynkuet as two small capsules (120 mg total) once a day at bedtime, with or without food.
Lynkuet (elinzanetant)
Approved Oct 2025 — the newest. Blocks NK1 + NK3. 120 mg at bedtime. No liver boxed warning. Baseline + 3-month liver test. Also helps sleep. Not for pregnancy.
Veozah (fezolinetant)
Approved May 2023 — the first in its class. Blocks NK3. 45 mg once daily. FDA boxed warning for liver injury. 6 blood tests in year one. More real-world history.
Brisdelle (paroxetine)
Approved 2013 — the original. Very low-dose SSRI (7.5 mg at bedtime). SSRI boxed warning (suicidal thoughts in young adults). Avoid with tamoxifen. Usually cheapest.
And then there’s hormone therapy— often called HRT or MHT. It isn’t “new,” but it matters here because, for women who can safely take it, hormones remain the most effective treatment for hot flashes, according to The Menopause Society. So you really have four lanes to consider, not one. Let’s line them up.
Lynkuet vs Veozah vs Brisdelle vs hormone therapy: the 2026 comparison
Here is the side-by-side most pages won’t give you — four hot flash options, with verified 2026 facts, in one table.The newest pill (Lynkuet) has the lighter blood-test schedule. The first non-hormonal pill (Veozah) has a longer track record but a liver warning. The oldest option (Brisdelle) is usually cheapest but carries different risks. Hormones may still be the most effective route — if you’re a candidate.
This table is for a conversation with your clinician, not for self-prescribing. Every fact below is drawn from FDA labels and manufacturer disclosures; see “How we verified this guide” near the end for sources and dates.
| Feature | Lynkuet (elinzanetant) | Veozah (fezolinetant) | Brisdelle (paroxetine 7.5 mg) | Hormone therapy (HRT/MHT) |
|---|---|---|---|---|
| What it is | Non-hormonal pill; blocks NK1 + NK3 brain receptors | Non-hormonal pill; blocks NK3 brain receptor | Non-hormonal; very low-dose SSRI (antidepressant), approved only for hot flashes | Estrogen (plus progesterone if you have a uterus) |
| FDA status | Approved Oct 24, 2025 — the newest | Approved May 2023 | Approved 2013 at this low dose | Long established; not new |
| How you take it | 120 mg (two capsules) once daily at bedtime | One 45 mg tablet once daily, any time | One 7.5 mg capsule at bedtime | Pill, patch, gel, spray, or vaginal — clinician decides |
| How well it works | ~74% drop in moderate-to-severe hot flashes at 12 weeks vs ~47% on placebo (OASIS-3 trial) | Roughly half, vs placebo, in its trials | More modest than the NK pills | Most effective option for women who can take it (per The Menopause Society) |
| Also helps with | Sleep (the NK1 piece) | — | — | Vaginal dryness, bone loss — depending on the product |
| Boxed warning? | No ✔ | Yes — rare serious liver injury (added Dec 2024) | Yes — suicidal thoughts in young adults (SSRI class) | CVD, breast cancer, and dementia language removed from 6 products Feb 2026 (endometrial warning kept on estrogen-alone) |
| Blood tests (year one) | Liver test before starting + once at 3 months (~2 draws) | Before starting, then monthly ×3, plus months 6 and 9 (~6 draws) | No set liver schedule | Depends on history; no fixed schedule |
| Key cautions | Pregnancy (not allowed), seizure history, daytime drowsiness, grapefruit/CYP3A4 meds | Cirrhosis, severe kidney disease, certain CYP1A2 meds | Reduces tamoxifen’s effect, bleeding risk with NSAIDs, MAOIs | Risk profile depends on age, history, and timing |
| What it does NOT treat | Vaginal dryness, bone loss | Vaginal dryness, bone loss | Broad menopause symptoms | (Treats the broadest range) |
| 2026 cost (before help) | ~$625/month (list price) | ~$583.50 WAC for 30 tablets (Jan 2026) | Often low; generic paroxetine 7.5 mg cheaper | Varies; generic estradiol/progesterone often low |
| With commercial insurance + savings card | As low as $25/month | $0 first month, then as low as $30/refill, commercial insurance only | Varies by plan | Varies by plan |
| Generic available? | No | No | Yes (generic paroxetine, 7.5 mg) | Yes for many products |
| Best for the person who says… | “I want the newest option, my sleep is wrecked, and I’d rather skip monthly blood draws.” | “I want a non-hormonal pill with more years on the market, and I’ll do the lab schedule.” | “Cost is my main barrier and I understand the SSRI risks.” | “I can take hormones and want relief beyond just hot flashes.” |
A note on the numbers: Lynkuet and Veozah were each tested against a placebo — not against each other. So the percentages above can’t be read as a head-to-head ranking. The differences you can fairly compare: the boxed warning, the number of blood draws, the sleep benefit, and the price.
Quick read of the table
- Want the newest, with strong trial results and the lighter lab schedule? Ask about Lynkuet.
- Want a non-hormonal pill with a longer track record? Ask about Veozah (and budget for the blood draws).
- Cost is the wall you keep hitting? Ask about Brisdelle or generic paroxetine — and other low-cost options below.
- You might be a hormone candidate and want broader relief? Put hormone therapy on the table.
- History of breast cancer or other cancer? Loop in your oncologist before assuming any path.
See which option fits your situation →
Answer a few quick questions about your symptoms and history, and get a personalized starting point — plus a checklist for your clinician.
Take the free quiz →Is the new hot flash medication a hormone? (No — here’s what that means)
No. Lynkuet is not a hormone and not HRT. It contains no estrogen and no progesterone.The FDA label describes it as an NK1 and NK3 receptor blocker — meaning it works on temperature-control signals in the brain, not on your hormone levels. Veozah and Brisdelle are non-hormonal too.
This is the whole reason these pills exist. A lot of women searching for them have been told they can’ttake hormones — because of a history of breast cancer, blood clots, stroke, or other conditions. Others simply don’t want hormones.
Fair warning before you celebrate
Non-hormonal does not mean side-effect-free. It does not mean no prescription, no blood tests, or no drug interactions. And — this surprises a lot of people — it does not automatically mean safer. Which brings us to the thing almost no one is connecting.
Dr. JoAnn Pinkerton, a menopause expert at UVA Health who helped run the U.S. Lynkuet trials, put it simply: she’s glad women who can’t or choose not to take hormones now have an option that’s effective and tested. That’s the shift these drugs represent.
Wait — is “non-hormonal” actually safer than hormones?
Not automatically. Safety depends on the specific drug and your health history — not on whether something is a hormone. Here’s the proof: two of the three FDA-approved non-hormonal hot flash pills carry the FDA’s most serious safety label (a “boxed warning”), while in February 2026 the FDA removed boxed warnings from six hormone products.
A boxed warning (you may have heard it called a “black box warning”) is the strongest safety alert the FDA puts on a medication. Here’s where they currently land:
| Medication | Boxed warning? | What it’s for | FDA label last revised |
|---|---|---|---|
| Lynkuet (elinzanetant) | No ✓ | — | |
| Veozah (fezolinetant) | Yes ⚠️ | Rare serious liver injury (added ) | |
| Brisdelle (paroxetine 7.5 mg) | Yes ⚠️ | Suicidal thoughts in young adults — a class-wide SSRI warning | |
| Six hormone products (Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, Estring) | Removed ✓ | CVD, breast cancer, and dementia language removed; endometrial warning kept on estrogen-alone |
What this means for you, in plain terms
Don’t choose a hot flash treatment based on the word “hormone-free” alone. A non-hormonal pill might be perfect for you — or a hormone product might be both safer andmore effective for your situation. The right answer comes from matching the specific drug’s risks to your specific health history. That’s a conversation, not a slogan.
On , the FDA approved labeling changes that removed the boxed warnings for cardiovascular disease, breast cancer, and probable dementia from six menopausal hormone products. One warning stays in place: the endometrial cancer concern remains on estrogen-alone systemic products, which is why women with a uterus are commonly given a progestogen alongside systemic estrogen. For the bigger picture, see our breakdown of the new HRT guidelines.
How do Lynkuet and Veozah actually work? (in plain English)
Both Lynkuet and Veozah work on the brain’s built-in thermostat.During menopause, falling estrogen throws off a cluster of nerve cells that help regulate body temperature, which narrows your “comfort zone” and triggers hot flashes. These pills calm that faulty signaling — they don’t add hormones back.
The everyday version
Think of certain brain cells as a thermostat that’s gotten oversensitive. Tiny temperature changes now flip it into “emergency cooling” mode — that sudden flush, the sweat, the heat climbing up your neck. The chemical messengers that push that thermostat are called neurokinins, and the docking stations they use are NK1 and NK3 receptors.
- Veozahplugs the NK3 dock only. That quiets the hot flash signal.
- Lynkuetplugs both the NK3 and NK1 docks. Blocking NK1 is thought to help with sleep, and in trials Lynkuet did improve sleep along with hot flashes and night sweats. Dr. Pinkerton pointed to that extra NK1 action as what may give Lynkuet a broader benefit.
That’s the real, practical difference between the two newest pills: same core target, but Lynkuet adds a sleep angle. Brisdelle works in a totally different way— it’s a low dose of an SSRI. The FDA label says the exact reason it eases hot flashes isn’t fully understood. It’s an older approach that helps some women, usually less powerfully than the NK pills.
How well do they work, and how fast?
In trials, all three non-hormonal pills reduced hot flashes — but each was tested against a placebo, not against the others. In the OASIS-3 trial (published in JAMA Internal Medicine), Lynkuet cut moderate-to-severe hot flashes by about 74% at 12 weeks, versus about 47% on placebo. Veozah cut them by roughly halfin its trials, and Brisdelle’s effect is more modest. Results vary from person to person.
The honest part — worth more than any percentage
Lynkuet’s trial number looks higher than Veozah’s. But the two drugs have never been tested against each other. So no one — not us, not an ad, not a TikTok — can truthfully tell you one beats the other. What you can compare is real and decision-shaping: the boxed warning, the number of blood draws, the sleep benefit, and the price. That’s exactly what this page does.
Lynkuet (OASIS trials)
- 3 trials (OASIS 1, 2, 3), 1,420+ women
- 74% drop in hot flashes at 12 weeks vs 47% placebo
- Improved sleep and mood in studies
- Does not improve vaginal dryness or bone density
- Year-long safety study included
Veozah (fezolinetant trials)
- 3 trials, 52 weeks, 1,100 women on drug
- Roughly half drop in hot flashes vs placebo
- On U.S. market since 2023; more real-world history
- Does not improve vaginal dryness or bone density
- Liver boxed warning added Dec 2024
Timing for all three
- Some women improved as early as week 1
- Measured results at 4 weeks and 12 weeks in trials
- Don’t expect overnight results
- Expect to know within a few weeks if it’s working
- Clinician will tell you when to reassess
The one honest downside (and why it might not matter to you)
These new non-hormonal pills only treat hot flashes and night sweats. They do nothing for vaginal dryness, painful sex, recurrent UTIs, or bone loss. They’re prescription-only, pricey before insurance, and need lab work. And for women who can safely take hormones, hormone therapy is usually more effective and treats more symptoms at once.
But for the millions of women who can’t take hormones, or who simply won’t, these pills are the most effective non-hormonal relief approved to date. If your main problem really is the hot flashes and the 3 a.m. soaked-sheets wakeups, a targeted pill that fixes exactly that — without touching your hormones — is the point, not a limitation.
Who’s a good fit for a new non-hormonal hot flash pill?
A new non-hormonal pill is worth asking about if your hot flashes or night sweats are moderate to severe and disruptive, and you can’t take hormones or prefer not to.It fits best when hot flashes and sleep are your main targets — not the full range of menopause symptoms.
These pills may be a strong fit if:
- Your hot flashes are frequent or severe
- Night sweats are wrecking your sleep (Lynkuet’s sleep benefit is a plus here)
- Hormones are off the table for you, or you just don’t want them
- The thing you most want fixed is the hot flashes, not every symptom
- You can complete the required screening and lab tests
- The cost works for you, with or without a savings program
They may not be the right fit if:
- Your main issues are vaginal dryness, painful sex, recurrent UTIs, or bone loss
- You’re pregnant, trying to get pregnant, or could be pregnant
- You have a liver, kidney, or seizure issue that makes them risky
- You can’t realistically afford the medication or keep up with monitoring
| If you’re… | A good next step to discuss is… |
|---|---|
| Unable to take hormones | A non-hormonal pill — Lynkuet, Veozah, or Brisdelle, with a clinician |
| Mostly losing sleep to night sweats | Lynkuet (it targets sleep too) |
| Looking for the broadest menopause relief | Whether hormone therapy fits you |
| A breast cancer survivor or on endocrine therapy | A menopause and oncology conversation first |
| Worried mainly about cost | Brisdelle/generic paroxetine, plus the coverage tips below |
| Nervous about frequent blood tests | Lynkuet’s lighter schedule vs Veozah’s |
| Not sure which symptoms are even connected | Our quiz, then a clinician checklist |
Build my treatment-path checklist →
Answer 8 quick questions and get a one-page list of exactly what to raise with your clinician — symptoms, history, and the right questions to ask. Free, private, no pressure.
Build my checklist →Who should be extra careful: the “ask first” screening lists
Some health conditions and medications change whether these drugs are safe for you.Before asking for any of them, check yourself against the list for that specific drug. These aren’t reasons to panic — they’re the exact things a good clinician will check anyway. Walking in already knowing your answers saves you time.
Before asking about Lynkuet
- Are you pregnant, trying to conceive, or possibly pregnant? (Not allowed in pregnancy)
- Do you have a history of seizures?
- Do you have liver disease or high liver enzymes?
- Do you have end-stage kidney disease?
- Do you take any “CYP3A4” medications, or eat grapefruit?
- Do you drive, work overnight, or operate machinery? (About 12% had drowsiness vs 3.5% on placebo)
Before asking about Veozah
- Do you have cirrhosis? (Hard “no” for Veozah)
- Do you have severe kidney disease or end-stage renal disease?
- Do you take a CYP1A2 inhibitor? (Ask your pharmacist to check your full list)
- Can you commit to the blood tests (before starting, monthly ×3, months 6 and 9)?
- Do you know the warning signs (yellow skin/eyes, dark urine, nausea, deep fatigue) — stop and call right away?
Before asking about Brisdelle
- Do you take an MAOI antidepressant? (Not allowed with Brisdelle)
- Are you on tamoxifen? Paroxetine can reduce how well tamoxifen works
- Do you take NSAIDs, aspirin, or blood thinners? (Higher bleeding risk)
- Are you pregnant or could you be? (Not allowed)
Calm reminder: a “yes” on any of these doesn’t always rule the drug out. It means it’s a screening question your clinician needs to weigh. That’s normal and good.
The monitoring reality: how many blood tests, really?
This is the practical difference that decides it for a lot of people. Lynkuet needs a liver blood test before you start and one more at three months — about two draws in your first year. Veozah needs a test before starting, then monthly for three months, plus months 6 and 9 — about six draws in your first year. Liver-enzyme elevations showed up in about 0.6% of Lynkuet users versus 2.3% of Veozah users in trials.
| Checkpoint | Lynkuet | Veozah |
|---|---|---|
| Before starting | ✅ Required | ✅ Required |
| Month 1 | — | ✅ Required |
| Month 2 | — | ✅ Required |
| Month 3 | ✅ Required | ✅ Required |
| Month 6 | — | ✅ Required |
| Month 9 | — | ✅ Required |
| Total, year one | ~2 draws | ~6 draws |
“Liver enzymes” (transaminases) are proteins your doctor measures with a simple blood test to check that your liver is healthy. Both NK pills can occasionally nudge them up, which is why both require a baseline check. The difference is how closely you’re watched afterward. In the year-long OASIS-3 trial, Lynkuet was not linked to liver toxicity. Veozah’s monitoring exists precisely because, rarely, the liver injury can be serious. Full Veozah liver warning guide →
How much do the new menopause hot flash medications cost in 2026?
The newest pills are expensive before insurance kicks in. Lynkuet’s list price is about $625 a month. Veozah’s list price (its “WAC”) is $583.50 for 30 tablets as of January 14, 2026. Both are brand-only — there’s no generic for either. With commercial insurance and a manufacturer savings card, both can drop dramatically: Lynkuet to as low as $25/month and Veozah to $0 the first month, then about $30 per refill.
| Option | Verified 2026 price anchor | Savings / access note | What to check before you fill |
|---|---|---|---|
| Lynkuet | ~$625/month list (Bayer/Reuters) | As low as $25/month with commercial insurance via the Bayer/BlinkRx program | Coverage, prior authorization, savings eligibility |
| Veozah | $583.50 WAC for 30 tablets (Astellas, Jan 14, 2026) | $0 first month, then as low as $30/refill, commercial insurance only | Whether your plan covers it, annual savings cap, step therapy |
| Brisdelle / generic paroxetine (7.5 mg) | Often low; the generic 7.5 mg hot-flash dose is inexpensive | Generics keep cost down | Whether the script is for brand Brisdelle or the generic; the tamoxifen interaction |
| Hormone therapy | Varies; generic estradiol/progesterone often low-cost | Many generics available | FDA-approved product vs. compounded; coverage; any labs/visits |
Important coverage trap
Those manufacturer savings cards generally do not work with Medicare, Medicaid, or other government plans. If you’re on a government plan, ask about your formulary, prior authorization, and whether a lower-cost option fits.
A script that saves you money and surprise
“Does this need prior authorization or step therapy, and is there a manufacturer savings card I qualify for?”
Ask this before you leave the pharmacy or visit. Those two questions head off the two most common cost shocks.
What if insurance won’t cover it (or you just can’t afford it)?
If Lynkuet or Veozah isn’t covered or isn’t affordable, you still have real, evidence-backed options.Lower-cost paths include generic paroxetine (the 7.5 mg hot-flash dose), other antidepressants used for hot flashes, gabapentin, oxybutynin, and non-drug approaches like cognitive behavioral therapy. Manufacturer patient-assistance programs may also help if you’re uninsured.
- •Generic paroxetine in the 7.5 mg hot-flash dose (Brisdelle’s generic): The budget non-hormonal option, with the SSRI cautions above.
- •Other SSRIs/SNRIs used off-label for hot flashes (e.g. venlafaxine): Good evidence; venlafaxine is tamoxifen-safe.
- •Gabapentin: A non-hormonal medicine that can ease hot flashes, especially at night.
- •Oxybutynin: Another non-hormonal option some clinicians use for VMS.
- •Cognitive behavioral therapy (CBT) or clinical hypnosis: Non-drug approaches with evidence behind them.
- •Hormone therapy: If you’re eligible, generic estradiol and progesterone are often low-cost.
One honest caution: don’t swap in supplements as a substitute for FDA-approved treatment. The Menopause Society’s review specifically lists over-the-counter supplements and herbal remedies among the options notrecommended for hot flashes, because the evidence doesn’t support them.
Want the full breakdown of which non-hormonal options have real evidence? See our non-hormonal menopause options guide.
Should you ask about a new pill — or hormone therapy instead?
If you can safely take hormones, hormone therapy may be your most effective choice — and it now treats more symptoms with fewer scary warnings than it did a year ago. If you can’t or won’t take hormones, the new non-hormonal pills are the strongest option you have. This isn’t “hormones versus the new pill” as a fight. It’s about which mechanism, safety profile, and cost fit you.
Hormone therapy may be the better call if:
- You’re a good candidate (clinician weighs your age, history, and timing)
- You have hot flashes plus other symptoms — vaginal dryness, bone concerns, broad changes
- You want the most effective hot-flash relief available and can take it safely
- You started menopause within the last 10 years (FDA’s Feb 2026 announcement noted benefits of early timing)
A non-hormonal pill may be the better call if:
- Hormones are medically off-limits for you
- You simply prefer to avoid hormones
- Hot flashes and night sweats are your main target
- Sleep improvement is also a priority (consider Lynkuet)
The breast cancer situation deserves a flag of its own
In the U.S., Lynkuet and Veozah are approved for menopausehot flashes — not specifically for hot flashes caused by breast-cancer treatment. (Researchers have studied Lynkuet for that group, and regulators in Europe approved that use, but the U.S. label is menopause VMS.) If your hot flashes are tied to cancer treatment or endocrine therapy, this is firmly oncology-and-menopause-specialist territory. And remember: paroxetine (Brisdelle) can reduce how well tamoxifen works.
If hormones turn out to be on the table for you and you want to weigh telehealth options, our HRT telehealth comparison walks through providers and how they differ. Use it only once a clinician agrees hormones are appropriate for you.
How do you actually get a prescription?
All four options — Lynkuet, Veozah, Brisdelle, and hormone therapy — are prescription-only. There is no over-the-counter version. You can get a prescription two ways: from your own gynecologist or primary-care doctor, or from a menopause-focused telehealth clinic that can evaluate you by video and order the lab tests these medications require.
- 1Get your facts together. Note how often your hot flashes hit, how badly they disrupt sleep, your full medication list, and your relevant history (liver, kidney, seizures, cancer, pregnancy possibility).
- 2Pick your route. Your existing doctor already knows your history. A menopause telehealth clinic is built for exactly this and can usually move faster — including ordering the baseline liver labs Lynkuet and Veozah need.
- 3Ask the targeted question (script below). So you compare options instead of just accepting the first one mentioned.
- 4Sort out cost. Using the coverage questions above before you fill.
Midi Health — one straightforward telehealth path
Midi Healthis a menopause-focused virtual clinic that evaluates patients by video, can order labs, and publishes clinical guidance on non-hormonal options. It’s one straightforward way to have this exact conversation with a licensed clinician — who decides what’s appropriate for you.
See if Midi is a fit and available in your state →Sponsored. Whether any specific medication is right for you is always a clinician’s decision based on your health.
Not ready to pick a provider?
A free 60-second path-finder that turns your symptoms and history into a clear plan and clinician checklist. No diagnosis, no prescription — just direction.
Map out my next step →What to bring to your clinician: the discussion checklist
The strongest move isn’t walking in and asking for “the newest pill.” It’s walking in with a focused checklist.Bring your symptom details, your medication list, your relevant history, your hormone preference, and your cost limits — and your clinician can match you to the right option faster.
Bring answers to these:
- How many hot flashes per day or week? How bad are the night sweats?
- How much is your sleep affected?
- Every medication and supplement you take (don’t forget heartburn meds and anything with a grapefruit interaction)
- Your view on hormones: open to them / not open / can’t take them / unsure
- Any cancer history or current endocrine therapy (like tamoxifen)
- Liver disease, kidney disease, or seizure history
- Any chance of pregnancy
- Your insurance type and your monthly cost ceiling
- What you most want fixed: fewer hot flashes, better sleep, broader symptoms, vaginal symptoms, mood, or bone health
A script that opens the right conversation
“I’ve read there’s a new non-hormonal hot flash medication called Lynkuet. Given my history and symptoms, should I be considering Lynkuet, Veozah, Brisdelle, hormone therapy, or something else?”
That one question turns a yes/no into a real comparison.
How we verified this guide
Last verified:
What we verified directly
- Lynkuet (elinzanetant) FDA label (revised Oct 2025) — approval date, NK1/NK3 mechanism, 120 mg bedtime dosing, pregnancy and seizure warnings, baseline + 3-month liver testing, drug interactions (CYP3A4, grapefruit), and most common side effects
- Veozah (fezolinetant) FDA label (revised Feb 2026) — the boxed warning for liver injury (added Dec 2024), the baseline + monthly-×3 + months 6 and 9 testing schedule, contraindications (cirrhosis, severe kidney disease, CYP1A2 inhibitors), and side effects
- Brisdelle (paroxetine 7.5 mg) FDA label (revised Feb 2025) — its approval for menopause hot flashes (not psychiatric use), bedtime dosing, the boxed warning for suicidal thoughts in young adults, and the tamoxifen interaction
- The FDA’s February 12, 2026 announcement removing boxed warnings from six named hormone products, and which warning was retained
- Lynkuet’s ~74% vs ~47% result — from the OASIS-3 trial published in JAMA Internal Medicine
- 2026 pricing — Veozah’s $583.50 WAC from Astellas (January 14, 2026) and Lynkuet’s ~$625 list price from Bayer and Reuters
- The Menopause Society position that hormone therapy remains the most effective treatment for hot flashes
What you should re-confirm yourself before acting
Exact pharmacy prices on the day you fill; your specific insurance coverage and prior-authorization rules; current savings-card terms; whether a given telehealth provider can evaluate you and prescribe in your state; and any FDA label updates after June 8, 2026.
Our promise on honesty
We compiled this from FDA records, manufacturer prescribing and pricing information, and published trial results. We don’t use “medically reviewed by” labels we can’t stand behind, and we don’t invent author credentials. And we don’t rank these medications by who pays us — because if we did, this page would be worthless to you.
FAQ: new menopause hot flash medication
- What is the newest medication for menopause hot flashes?
- The newest is Lynkuet (elinzanetant), from Bayer, approved by the FDA on October 24, 2025 and available in U.S. pharmacies since November 2025. It’s a non-hormonal pill and the first to block two brain receptors at once (NK1 and NK3). The other newer non-hormonal option is Veozah (fezolinetant), approved in 2023.
- Is Lynkuet a hormone?
- No. Lynkuet is not estrogen, progesterone, or hormone therapy. It’s a non-hormonal medication that blocks NK1 and NK3 receptors in the brain’s temperature-control center. That’s what makes it an option for women who can’t or don’t want to take hormones.
- Is Lynkuet better than Veozah?
- There’s no honest head-to-head answer, because the two were never tested against each other — only against placebo. What you can compare: Lynkuet is newer, also helps sleep, has no boxed warning, and needs fewer blood tests. Veozah has a longer U.S. track record and a slightly lower list price, but it carries a boxed warning for rare liver injury and requires monthly liver tests early on.
- Are the new hot flash medications hormones?
- No. Lynkuet, Veozah, and Brisdelle are all non-hormonal. None contains estrogen or progesterone. Lynkuet and Veozah work on brain temperature signals; Brisdelle is a low-dose SSRI.
- Is there a generic for Lynkuet or Veozah?
- No. There’s no generic version of Lynkuet or Veozah in the U.S. right now — both are brand-only, which is part of why they’re pricey before insurance. Brisdelle does have a generic (paroxetine in the 7.5 mg hot-flash dose).
- Why does Veozah have a boxed warning, and is it safe?
- In December 2024 the FDA added a boxed warning to Veozah for rare but serious liver injury. It remains an approved, widely used medication, but it requires liver blood tests before starting, monthly for the first three months, and again at months 6 and 9. Stop it and contact your prescriber immediately if you notice signs of liver trouble like yellowing skin, dark urine, or deep fatigue.
- What are the side effects of Lynkuet?
- The most common are mild: headache, fatigue, dizziness, and drowsiness (daytime drowsiness or dizziness affected about 12% of users). It can raise liver-enzyme levels, is not allowed in pregnancy, is used cautiously if you have a seizure history, and shouldn’t be combined with grapefruit or strong CYP3A4 medications.
- How much does the new hot flash medication cost without insurance?
- Lynkuet’s list price is about $625 a month, and Veozah’s list (WAC) price is $583.50 for 30 tablets as of January 2026. Both are brand-only with no generic. With commercial insurance and a manufacturer savings card, both can drop to around $25–$30 a month. Those savings cards don’t work with Medicare or Medicaid.
- Do the new pills work better than hormone therapy?
- No. For women who can safely take it, hormone therapy is still considered the most effective treatment for hot flashes. The new non-hormonal pills are the leading choice when hormones are off-limits or unwanted.
- Can breast cancer survivors take Lynkuet or Veozah?
- In the U.S., Lynkuet and Veozah are approved for menopause hot flashes. These non-hormonal drugs are sometimes relevant for women who can’t take estrogen, but a breast-cancer history makes this specialist-first: your oncologist must weigh in — partly because paroxetine (Brisdelle) can reduce tamoxifen’s effectiveness.
- Do these pills help with vaginal dryness or only hot flashes?
- Only hot flashes and night sweats. Neither Lynkuet nor Veozah treats vaginal dryness or other genitourinary symptoms. Those are treated separately — low-dose vaginal estrogen is one common option, though the right choice depends on your health history.
- How do I get a prescription for the new hot flash medication?
- All of these are prescription-only. You can get a prescription from your own gynecologist or primary-care doctor, or from a menopause-focused telehealth clinic that can evaluate you by video and order the required labs. There is no over-the-counter version.
Sources
- FDA Prescribing Information — LYNKUET (elinzanetant), revised 10/2025.
- FDA Prescribing Information — VEOZAH (fezolinetant), revised 02/2026 (includes boxed warning).
- FDA Drug Safety Communication — boxed warning for serious liver injury with Veozah (December 2024).
- FDA Prescribing Information — BRISDELLE (paroxetine 7.5 mg), revised 02/2025.
- FDA News Release — “FDA Approves Labeling Changes to Menopausal Hormone Therapy Products,” February 12, 2026.
- Astellas — Wholesale Acquisition Cost disclosure for Veozah, pricing as of January 14, 2026.
- Reuters — Bayer’s Lynkuet FDA approval and pricing, October 24, 2025.
- Panay N, Joffe H, Maki PM, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause (OASIS-3). JAMA Internal Medicine, 2025.
- The Menopause Society — 2023 nonhormone therapy position statement.
- UVA Health (Dr. JoAnn Pinkerton) — commentary on elinzanetant’s FDA approval, December 2025.
Medical disclaimer: This guide is educational and is not medical advice. It does not diagnose any condition or recommend any specific treatment for you. Lynkuet, Veozah, Brisdelle, and hormone therapy all require evaluation by a licensed clinician. Always talk with your own healthcare provider before starting, stopping, or changing any medication.
Still not sure which HRT program is right for you?
Take our free 60-second matching quiz. It turns everything you just read into a clear, personal plan — and the exact questions to walk in with.
Take the free 60-second matching quiz →No diagnosis. No prescription. Just clarity, and the right questions for your clinician.